
Press Release
Cyclarity Therapeutics Closes Tranche 1 of Series A Funding Round
Cyclarity will use funds from this round to commence clinical trials later this month for the development of UDP-003, a novel therapeutic designed to reduce atherosclerotic plaque accumulation by targeting its root cause, the accumulation of toxic oxidized cholesterol in cells and tissues.